08th February 2022 | Pharma Updates
SII Scores Approval to Manufacture Omicron Vaccine
DCGI has cleared SII’s proposal to make a vaccine against Omicron infection.
Corbevax to Cost Rs 145
HLL Lifecare has issued an order of Corbevax to drugmaker Biological E.
Drug for CAD Is Now Available
Cold Agglutinin Disease is affecting the health of around 5000 people in the US.
Sanofi gets FDA Clearance to Treat Rare Blood Disorder
The drug major has introduced this drug with the acquisition of Bioverativ.
Viiv Healthcare to Launch Cabenuva
Last year, the drug regulator okayed this drug use once a month in HIV positive patients.
Azurity Pharma to Present Drug for Patients with MS
Fleqsuvy is also indicated for the treatment of people suffering from spinal cord diseases and spinal injury.
Ascletis Introduces New Inhibitor for Tumour Patients
ASC61 presents good efficacy against solid tumours. The first patient is expected to be dosed in the first half of this year.
AbbVie Secures Approval to Launch Rinvoq
The drug is indicated to treat adults and kids around 12 years old with moderateto-severe eczema whose condition didn’t improve with other drugs.
AusCann gets Memorandum of Conference from FDA for Vet Drug
CPAT-01 is made to manage pain, inflammation and quality of life in dogs with osteoarthritis.
New Anticancer Drug Likely to be Available
In January 2021, Yuhan’s Leclaza received conditional approval as a second-line treatment for estimated glomerular filtration rate T790M mutation-positive Non-Small-Cell Lung Cancer.